BioDlink announced that its self-developed Bevacizumab Injection (Pusintin®) has received marketing approval from NAFDAC ...

BioDlink's Bevacizumab Injection has been granted marketing authorization by Nigeria's National Agency for Food and Drug Administration and Control ...

To evaluate long-term outcomes of anti-VEGF therapy for neovascular age-related macular degeneration (nAMD) in the Netherlands (NL), where bevacizumab is the mandated first-line drug, compared to high ...

Intravitreal anti-VEGF agents are linked to a slight increase in the risk for stroke in patients with age-related macular degeneration, but only for about 2 months after the last injection.

Outlook Therapeutics, Inc. (Nasdaq: OTLK), today announced the Scottish Medicines Consortium (SMC) approval of LYTENAVA™ (bevacizumab gamma) for the treatment of wet age-related macular degeneration ...

Background Data comparing systemic exposure and systemic vascular endothelial growth factor (VEGF) suppression of ranibizumab, bevacizumab and aflibercept following intravitreal injection are lacking.

Receiving the SMC recommendation of LYTENAVA™ (bevacizumab gamma) for patients with wet AMD is a significant milestone for our company and a testament to our commitment to improving patient outcomes,” ...

GMP certification from Argentina, marking a key step in its global expansion and regulatory recognition.Scalable, Trustworthy Solutions: ...

Detailed price information for Outlook Therapeutics Inc (OTLK-Q) from The Globe and Mail including charting and trades.

Aims: The aim of the study was to evaluate functional and anatomical changes after intravitreal bevacizumab (Avastin®) in eyes with persistent macular oedema secondary to branch retinal vein occlusion ...

Avastin hasn’t been reported to interact significantly with other drugs. However, this doesn’t mean that interactions aren’t possible. For example, new drugs may be developed that may ...